Friday, June 02, 2006

FDA & BMS's dasatinib: the shape of things to come

Insider read in the Wall Street Journal yesterday that Dr Andrew von Eschenbach, is finally going to step down as head of the US NCI to "focus" on his job as head of the FDA on 10 June.

On the same day he notes how the FDA Oncological Drug Advisory Committee is conveniently moving their decision-making meeting on the NDA for BMS's dasatinib to Atlanta, the site of the ASCO meeting and the June haven for every investment leech in the civilized world.

Oh, and of course, the ODAC meeting will be followed by an "educational symposium" on the drug at ASCO.

The only thing missing is an invitation to the champagne blowout after the approval decision is recommended to the FDA!

Is this what we have to look forward to under von Eschenbach's FDA???

No comments: